Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy

Phenotypic assays of hepatitis B virus (HBV) play an important role in research related to the problem of drug resistance that emerges during long‐term nucleot(s)ide therapy in patients with chronic hepatitis B. Most of the phenotypic assay systems that are available currently rely on the transfecti...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 84; no. 1; pp. 34 - 43
Main Authors Hu, Jie-li, Cui, Jing, Guo, Jin-jun, Zhang, Wen-lu, Cai, Xue-fei, Yuan, Zuo-wei, Li, Qing-ling, Deng, Xiao-yan, Zeng, Ai-zhong, Hu, Yuan, Tang, Ni, Huang, Ai-long
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2012
Wiley
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Phenotypic assays of hepatitis B virus (HBV) play an important role in research related to the problem of drug resistance that emerges during long‐term nucleot(s)ide therapy in patients with chronic hepatitis B. Most of the phenotypic assay systems that are available currently rely on the transfection of recombinant replication‐competent HBV DNA into hepatoma cell lines. Cloning clinical HBV isolates using conventional digestion‐and‐ligation techniques to generate replication‐competent recombinants can be very difficult because of the sequence heterogeneity and unique structure of the HBV genome. In this study, a new strategy for constructing an HBV 1.1× recombinant was developed. The core of this strategy is the “fragment substitution reaction” (FSR). FSR allows PCR fragments to be cloned without digestion or ligation, providing a new tool for cloning fragments or genomes amplified from serum HBV DNA, and therefore making the assay of HBV phenotypes more convenient. Using this strategy, a phenotypic assay was performed on an HBV strain carrying an rtS246T variant isolated from a patient with chronic hepatitis B that was only responsive partially to entecavir therapy. The results indicated that this strain is sensitive to entecavir in vitro. J. Med. Virol. 84:34–43, 2011. © 2011 Wiley Periodicals, Inc.
Bibliography:ArticleID:JMV22260
National High Technology Research Development Program of China - No. 2007AA02Z494
istex:033DFCB64A53A3654D37846AEDBCC8D9467E0934
Natural Science Foundation Project of CQ CSTC - No. cstc2011jjA10005
ark:/67375/WNG-DHNTQRDP-X
The National Natural Science Foundation of China - No. 81000732; No. 30972583; No. 30972587
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Case Study-2
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0146-6615
1096-9071
1096-9071
DOI:10.1002/jmv.22260